Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)

This trial tests obecabtagene autoleucel (obe-cel), a personalized CAR-T cell therapy, in adults with relapsed or treatment-resistant B-cell acute lymphoblastic leukemia (B-ALL) — a cancer of white blood cells. Your own immune cells are collected, genetically engineered to recognize leukemia, and given back to fight the cancer. **You may be eligible if...** - You are an adult with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or stopped responding to treatment - You have received at least one prior treatment for your leukemia - Your cancer cells express a protein called CD19 (which the therapy targets) - Your overall health and organ function are adequate for CAR-T therapy **You may NOT be eligible if...** - Your leukemia does not express CD19 - You have active central nervous system (brain/spinal) involvement by leukemia - You have a serious infection or uncontrolled illness - Your heart, liver, or kidney function is significantly impaired Talk to your doctor to see if this trial is right for you.